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Background: In a classic model, Giα proteins including Gi1α, Gi2α and Gi3α are important for transducing signals
from Giα protein-coupled receptors (GiαPCRs) to their downstream cascades in response to hormones and
neurotransmitters. Our previous study has suggested that Gi1α, Gi2α and Gi3α are also important for the activation
of the PI3K/Akt/mTORC1 pathway by epidermal growth factor (EGF) and its family members. However, a genetic
role of these Giα proteins in the activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) by
EGF is largely unknown. Further, it is not clear whether these Giα proteins are also engaged in the activation of
both the Akt/mTORC1 and ERK1/2 pathways by other growth factor family members. Additionally, a role of these
Giα proteins in breast cancer remains to be elucidated.
Results: We found that Gi1/3 deficient MEFs with the low expression level of Gi2α showed defective ERK1/2
activation by EGFs, IGF-1 and insulin, and Akt and mTORC1 activation by EGFs and FGFs. Gi1/2/3 knockdown breast
cancer cells exhibited a similar defect in the activations and a defect in in vitro growth and invasion. The Giα
proteins associated with RTKs, Gab1, FRS2 and Shp2 in breast cancer cells and their ablation impaired Gab1’s
interactions with Shp2 in response to EGF and IGF-1, or with FRS2 and Grb2 in response to bFGF.
Conclusions: Giα proteins differentially regulate the activation of Akt, mTORC1 and ERK1/2 by different families of
growth factors. Giα proteins are important for breast cancer cell growth and invasion.
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cancerIntroduction
Giα proteins including Gi1α, Gi2α and Gi3α transduce sig-
nals from Giα protein-coupled receptors (GiαPCRs) to
downstream pathways in hormone and chemo-attractant
signaling. Recent genetic evidence strongly suggests that
Giα proteins also play an important role in cell growth
and tumorigenesis. Active mutants of Gi2α promote cell
transformation and are associated with ovarian cancer
[1,2], whereas Gi2α deficiency results in the development
of spontaneous colitis and colon cancer in mice [1]. Also,* Correspondence: jm@ucla.edu; wchu@cc.hawaii.edu
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stated.Gi3α ablation impairs the antiautophagic response to insu-
lin in mouse liver, and Gi2α and Gi3α double deficiency
leads to severe embryonic growth retardation and the sub-
sequent embryonic lethality [3], which, at least in part,
are similar to phenotypes of many growth factor recep-
tor deficiencies. However, how these Giα proteins are
implicated in cell growth and tumorigenesis remains
poorly understood.
It is known that the extracellular signal-regulated ki-
nases (ERK1/2) and PI3K/Akt/mTORC1 pathways play
an essential role in cell growth and malignant transform-
ation. Both GiαPCRs [4] and growth factor receptors,
which are also called receptor tyrosine kinases (RTKs),
can activate them in response to their respective ligands.
The GiαPCRs-triggered activation is mainly mediated bytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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or transmit signals to ERK1/2 through Src-, Shc- and
Grb2- dependent and independent mechanisms [6-8].
This activation is sensitive to the treatment of Bordetella
pertussis toxin (PTX), which blocks the interaction of Giα
proteins with GiαPCRs [6,9,10].
The RTK-triggered activation of these two pathways
by growth factors, including basic fibroblast growth fac-
tor (bFGF), epidermal growth factor (EGF), heparin-
binding EGF-like growth factor (HB-EGF), insulin and
insulin-like growth factor 1 (IGF-1) [11,12], is mainly
mediated by adaptor proteins and the phosphatase Shp2.
The established features of ERK1/2 activation by EGF,
IGF-1 and insulin are that activated RTKs recruit Grb2,
insulin receptor substrates (IRSs) and Grb2-associated
binding protein 1 (Gab1) to interact with Shp2 leading
to ERK1/2 activation [13-17]. Intriguingly, Gab1 is also
recruited to the FGF receptor (FGFR) and forms a com-
plex with Grb2 and the FGF receptor substrate 2 (FRS2),
but it is not involved in ERK1/2 activation by FGFs [18].
Instead, FRS2 and Grb2 as well as their interaction are
essential for ERK1/2 activation by FGFs. Further, Gab1
is not implicated in the activation of the PI3K/Akt/
mTORC1 pathway by insulin or IGF-1. In its place, IRSs
are recruited to insulin receptors (IRs) or IGF-1Rs, inter-
act with PI3Kp85 and activate PI3K [19] generating PIP3
and triggering phosphorylation of Akt on threonine (T)
308 by PDK1 and serine (S) 473 by the mammalian tar-
get of rapamycin complex 2 (mTORC2). Activated Akt
triggers the activation of the mammalian target of rapa-
mycin complex 1 (mTORC1), which in turn phosphory-
lates 4E-BP1 and S6 kinase (S6K), which phosphorylates
S6. Conversely, Gab1 is critical for EGFR- and FGFR-
mediated activation of the PI3K/Akt/mTORC1 pathway
by EGF or FGFs. Gab1 is tyrosine (Y)-phosphorylated and
then interacts with Grb2 and PI3Kp85. These interactions
are essential for PI3K activation by EGF and FGFs.
It is known that GiαPCRs can trans-activate RTKs,
and that both of them share some downstream adaptor
proteins such as Grb2 and Shc to activate ERK1/2. How-
ever, PTX and Gβ blocking peptides can inhibit the acti-
vation of Akt and ERK1/2 by GiαPCRs ligands, but not
EGF [20,21]. Thus, it is unknown whether Giα proteins
can regulate RTKs-mediated activation of the ERK1/2
and PI3K/Akt/mTORC1 pathways by grow factors.
We previously reported that loss of Gi1α and Gi3α in
mouse embryonic fibroblasts (MEFs) resulted in a defect
in Akt and mTORC1 activation by EGF [20]. Yet, it is
largely unknown whether these Giα proteins regulate
ERK1/2 activation by EGF or ERK1/2, Akt and mTORC1
activation by other growth factors. Additionally, a role of
the Giα proteins in breast cancer pathogenesis is unre-
vealed. In this study, we investigated a role of the Giα
proteins in ERK1/2, Akt and mTORC1 activation bydifferent families of growth factors in mouse embryonic
fibroblasts and in human breast cancer cells.Results
Giα proteins differentially regulate the activation of the
ERK1/2 and Akt/mTORC1 pathways by growth factors in
mouse embryonic fibroblasts
To elucidate a role for Giα proteins in the activation of
ERK1/2, Akt and mTORC1 in response to growth fac-
tors, we used wild type (WT) and Gi1α and Gi3α double
knockout (Gi1/3 DKO) MEFs [20]. First, we examined
the expression levels of Gi1α, Gi2α and Gi3α in MEFs. As
shown, both Gi2α and Gi3α were relatively abundant, but
Gi1α was expressed at a low level and it required a longer-
exposure for a clear signal (Additional file 1: Figure S1A).
Interestingly, Gi2α expression level was obviously lower in
Gi1/3DKO MEFs than that in WT MEFs (Additional
file 1: Figure S1A) indicating that loss of Gi1α and Gi3αmight
subsequently influence the expression of Gi2α in MEFs.
WT and Gi1/3 DKO MEFs were then treated with EGF,
HB-EGF, aFGF, bFGF, IGF-1, insulin, and PDGF and the
activation statuses of several intracellular signaling mole-
cules were examined. The expression levels of major relay
molecules in the ERK1/2 and Akt pathways in Gi1/3 DKO
MEFs were similar to WT controls (Additional file 1:
Figures S1B to S1D), whereas the phosphorylation levels of
ERK1/2, Akt, and mTORC1’s downstream events including
4E-BP1 and S6 were altered (Figure 1). Kinetic experiments
showed that Gi1/3 DKO MEFs exhibited a severe defect in
phosphorylation of ERK1/2(T202/Y204), Akt (S473) and
S6(S235/236) in response to EGF and HB-EGF (Figures 1A
and 1B). Consistent with our previous study [20], loss of
Gi2α in MEFs did not have an apparent effect on ERK1/2
activation by EGF (Additional file 1: Figure S1E).
Surprisingly, loss of Gi1α and Gi3α largely impaired phos-
phorylation of Akt(S473) and S6(S235/236) in response to
aFGF and bFGF, but had no apparent effect on ERK/12
(T202/Y204) phosphorylation (Figures 1C and 1D). In con-
trast to the FGF response, the Gi1/3 deficiency largely de-
creased ERK1/2(T202/Y204) phosphorylation in response
to IGF-1 and insulin (Figures 1E and 1F), whereas this defi-
ciency only led to a minor defect in Akt(S473) phosphoryl-
ation [20]. Interestingly, S6(S235/236) phosphorylation was
largely impaired in the deficient cells (Figures 1E and 1F).
To determine if GiαPCRs are involved in the activation of
ERK1/2 by EGF, we treated cells with Giα protein inhibitor
PTX. Consistent with our previous report, EGF-induced
ERK1/2 activation was not reduced by PTX treatment
(Additional file 1: Figure S1F) [20]. However, IGF-1-
induced ERK1/2 activation was inhibited by PTX treat-
ment (Additional file 1: Figure S1F).
Also, loss of Gi1α and Gi3α clearly reduced phosphor-
ylation of Akt(S473), S6(S235/236), 4E-BP1(S65) and
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Figure 1 Giα proteins regulate differential activation of Akt, mTORC1 and ERK1/2 by growth factors. (A-F) WT and Gi1/3 DKO MEFs were
treated with (A) EGF (100 ng/ml), (B) HB-EGF (100 ng/ml), (C) aFGF (25 ng/ml), (D) bFGF (25 ng/ml), (E) IGF-1 (20 ng/ml), and (F) insulin (1 μg/ml
at the indicated time points. p-ERK (T202/Y204), p-AKT (S473), p-S6 (S235/236), or β-actin were detected by immunoblotting (IB) analysis. The
experiments were performed more than six times and similar results were obtained. (G) WT and Gi1/3 DKO MEFs were treated with PDGF for
10 minutes (min) at the indicated doses. p-ERK(T202/Y204), p-AKT(S473), p-S6(S235/236), or β-actin were detected by IB. The experiment was
repeated three times and similar results were obtained.
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http://www.biosignaling.com/content/12/1/10ERK1/2(T202/Y204) in response to PDGF at low doses
of 0.12, 0.36 or 1.1 ng/ml (Figure 1G). However, the de-
fect in this phosphorylation was not observed in the
deficient cells in response to PDGF at high doses
(Figure 1G) [20] indicating that Gi1α and Gi3α proteins
regulate the activation of Akt, mTORC1 and ERK1/2 by
PDGF in a dose dependent manner.
To confirm the above observations, we used RNA inter-
ference (RNAi) and reconstitution strategies. As shown,
Gi3α was clearly knocked down, whereas Gi1α was weakly
detected in MEFs (Figures 2A to 2C). Consistent with
above results in Figure 1, the combined knockdown of
Gi1/3 impaired ERK1/2(T202/Y204) phosphorylation in
response to EGF and IGF-1, and reduced Akt(S473) and S6
(S235/236) phosphorylation in response to EGF and bFGF
(Figures 2A to 2C). Reintroduction of both Gi1α and Gi3α,
or Gi3α alone partially restored phosphorylation of ERK1/2
(T202/Y204), or Akt(S473) and S6(S235/236) in Gi1/3
DKOMEFs in response to EGF, bFGF, or IGF-1 (Figures 2D
to 2F).
Taken together, our experimental results demonstrate
that Gi1α, Gi2α and Gi3α are functionally distinct in
RTKs-mediated activation of ERK1/2, Akt and mTORC1
in growth factor signaling (Table 1).
Giα proteins differentially regulate ERK1/2, Akt and
mTORC1 activation in breast cancer cells and are
important for their in vitro growth and invasion
Growth factor signaling plays a vital role in breast cancer
pathogenesis [22-24]. We investigated whether Gi1α, Gi2α0 5’ 0 5’
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Figure 2 Knockdown of Giα proteins down regulates Akt and ERK act
activation by EGF, bFGF and IGF-1. (A-C) WT MEFs transfected with siRN
(100 ng/ml), (B) bFGF (25 ng/ml), or (C) IGF-1 (20 ng/ml) for the indicated
Gi1α (Gi1) and Gi3α (Gi3) were detected by IB. The experiments were repea
MEFs were transfected with empty vector and Gi1/3 DKO MEFs were transf
were treated with (D) EGF (100 ng/ml), (E) bFGF (25 ng/ml) or (F) IGF-1 (20
p-S6(S235/236), or β-actin, Gi1α and Gi3α were detected by IB. The experim
were obtained.and G3α also regulate ERK1/2, Akt and mTORC1 activa-
tion by growth factors in breast cancer cells. Knockdown
of Gi1/3 in MDA-MB-231-D3H2-LN (MB231) (Caliper
Life Science), which expressed abundant Gi2α and Gi3α as
well as detectable Gi1α (Figures 3A to 3C), had a less strik-
ing effect on phosphorylation of ERK1/2(T202/Y204), Akt
(S473) and S6(S235/236) than that in MEFs in response to
EGF (Figure 3A). Knockdown of Gi2α reduced Akt(S473)
phosphorylation but did not impair phosphorylation of
ERK1/2 and S6(S235/236) by EGF (Additional file 2:
Figure S2). However, knockdown of Gi1α, Gi2α and G3α
(Gi1/2/3) largely impaired this phosphorylation by EGF
(Figure 3A) indicating that all three Giα proteins are im-
portant for the activation of Akt, mTORC1 and ERK1/2
by EGF. Similarly, knockdown of Gi1/2/3 led to a clear
defect in phosphorylation of Akt(S473) and S6(S235/
236) but not ERK1/2(T202/Y204) in response to bFGF
(Figure 3B). Knockdown of either Gi1/3 or Gi1/2/3
clearly impaired ERK1/2 phosphorylation, and slightly
reduced Akt(S473) phosphorylation in response to IGF-1
(Figure 3C).
Because Akt and ERK1/2 signaling is required for cell
growth and migration in response to growth factors [25],
based on above observations, we reasoned that Giα pro-
teins are involved in growth and invasion of breast can-
cers in response to EGF, bFGF, IGF-1 and FBS. To test
this hypothesis we performed in vitro growth and inva-
sion assays. We observed that knockdown of Gi1/2/3
not only clearly reduced the growth rate of breast cancer
cells (Figures 4A and 4B, Additional file 3: Figure S3),0 5’ 0 5’
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Table 1 Pathway activation by growth factors requires Ga proteins
EGF, HB- EGF, PDGF (low doses) Insulin, IGF aFGF, bFGF PDGF (high doses)
Akt-mTORC1 pathway + - + -
ERK pathway + + - -
+Giα proteins are required; - Giα proteins are not required.
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response to EGF, bFGF, IGF-1 and FBS (Figures 4C and
4D). Interestingly, knockdown of Gi1/3 reduced the in-
vasion ability of breast cancer cells in response to these
growth factors, although the reduction was not signifi-
cant (Figures 4C and 4D). Additionally, knockdown of
Gi2α slightly reduced EGF-, bFGF-, or IGF-1-induced
breast cancer invasion (Additional file 4: Figure S4).
Taken together, our results suggest that Giα proteins
promote growth and invasion of breast cancer cells.
To understand how Giα proteins regulate ERK1/2, Akt
and mTORC1 activation and breast cancer invasion in-
duced by growth factors in normal and breast cancer cells,
we first examined whether Giα proteins are involved in
the activation of FAK1, which is important for cell migra-
tion, and Shp2, which is critical for the activation of
ERK1/2 by EGF and IGF-1. Consistent with our previous
report [20] and above results, Gi1/3 DKO MEFs exhibited
a defect in phosphorylation of Akt(S473), ERK1/2 and
Gab1(Y627) in response to EGF (Figure 5A; Additional
file 5: Figure S5A). Also, Gi1/3 DKO MEFs showed im-
paired S6(S235/236) and Shp2 phosphorylation in re-
sponse to IGF-1 (Figures 5B; Additional file 5: Figure
S5B), and diminished Shp2 phosphorylation in response
to EGF (Figure 5A) and bFGF (Figure 5C), whereas they
showed a slightly reduced FAK1(Y397) phosphorylation
in response to EGF, bFGF and IGF-1 (Figures 5A to 5C).
Next, we examined whether Giα proteins associate
with growth factor receptors, their downstream adaptor
proteins and Shp2. As shown, bFGF induced Gi3α’s asso-
ciations with p-FGFR and Gab1 (Figure 6A), but did not
further augment the pre-association of Gi3α with FRS2
(Figure 6A). EGF induced the associations of Gi3α with
p-EGFR, Gab1 and Shp2 (Figures 6B to 6D) in breast
cancer cells.
Because Gab1’s association with Shp2 is critical for
ERK1/2 activation by EGF and IGF-1 [15,16,26], and be-
cause Grb2’s association with FRS2 is critical for this ac-
tivation by bFGF [18,27], we determined if Giα proteins
are important for these associations. As shown, EGF in-
duced Gab1’s interaction with Shp2 in WT cells, but this
interaction was impaired in Gi1/3 DKO MEFs (Figure 6E).
The interaction of Gab1 with Grb2, which is critical foractivation of the PI3K/Akt pathway by FGF [18], was also
impaired in Gi1/3/ DKO MEFs (Figure 6F). Conversely,
Grb2’s interaction with FRS2 was intact in Gi1/3 DKO
MEFs (Figure 6F). Taken together, our results suggest that
Giα proteins are important for Gab1’s interaction with
Shp2 in response to EGF and IGF-1, and Grb2’s inter-
action with Gab1 in response to bFGF.
Discussion
Giα proteins are known to transduce signals from
GiαPCRs to their downstream cascades and function at
the inner surface of the cell membrane. Here, we dem-
onstrate that Giα proteins also act as transducers for dif-
ferential RTK-mediated growth factor signaling. Giα
proteins form a complex with RTKs and are important
for phosphorylation of Gab1 and Shp2, the association
of Gab1 with Shp2, as well as the interaction of Gab1
with Grb2 leading to activation of the ERK1/2 and Akt/
mTORC1 signaling pathways.
Functional differences among Giα proteins in the
regulation of growth factor signaling
Genetic evidence reveals that Gi2/3α DKO mice die be-
tween embryonic days 9 and 10 due to severe mass
growth retardation [3]. Although the exact death reason
is currently unclear, the phenotype of the embryonic le-
thality strongly suggests that Giα proteins play an essen-
tial role in the cell proliferation and growth and survival
of embryos.
There are several avenues for Giα proteins to contrib-
ute to proliferation and growth. One of them is the acti-
vation of GiαPCRs, which transduce signals from their
agonists to their downstream PTX-sensitive signal cas-
cades such as the PI3K/Akt/mTORC1 and ERK1/2 sig-
naling pathways [4]. Activated GiαPCRs induce guanine
nucleotide exchange at Giα proteins leading to their dis-
sociation from Gβγ subunits. Dissociated Gβγ can trig-
ger the activation of the both pathways [6-8].
Another route is the crosstalk between GiαPCRs and
RTKs. RTKs can be transactivated by their agonists, which
are either expressively induced by activation of GiαPCRs
or secreted via GiαPCR-induced shedding of precursors of
growth factors such as pro-HB-EGF [28,29]. Secreted
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Figure 3 Giα proteins regulate differential activation of ERK1/2, Akt and mTORC1 in breast cancer cells in response to EGF, bFGF and
IGF-1. MB231 cells were transfected with mock or siRNA duplexes (combination of Gi1α and Gi3α, or Gi1α, Gi2α and Gi3α). Cells were then treated
with (A) EGF (100 ng/ml), (B) bFGF (25 ng/ml), or (C) IGF-1 (20 ng/ml) for the indicated time durations. p-AKT (S473), p-ERK (T202/Y204), p-S6
(S235/236), Gi1α (Gi1), Gi2α (Gi2), Gi3α (Gi3) or β-actin were detected by IB. The experiments were repeated two to three times and similar results
were obtained.
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Figure 4 Giα proteins are critical for breast cancer cell invasion in response to EGF, bFGF and IGF-1. MB231 cells were transfected with
scrambled or siRNA duplexes (combination of Gi1α and Gi3α, or Gi1α, Gi2α and Gi3α). After 24 hours, cells were trypsinized. (A-B) Cells were
seeded in 6-well plates, grown in DMEM containing 5% or 10% FBS and followed for up to 6 days. (C-D) Cells were seeded in new plates for
another 48 hours. Cells were re-trypsinized, seeded into 8 μm transwells pre-coated with matrigel and exposed to EGF (100 ng/ml), bFGF
(25 ng/ml), IGF-1 (20 ng/ml), 10% FBS or left untreated (with serum free medium) for 36 hours. Penetrated cells were stained and recorded by
an Olympus CKX41 microscopy with an Infinity 2 camera. *P value <0.01 (invaded breast cancer cells transfected with Gi1α, Gi2α and Gi3α siRNA
duplexes were compared with cells transfected with scrambled siRNA duplexes). The experiments were repeated three times and similar results
were obtained.
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tiple important signaling pathways including the PI3K/
Akt/mTORC1 and ERK1/2 pathways. The GiαPCR-medi-
ated shedding of HB-EGF is PTX sensitive, whereas
EGFR-mediated activation of the PI3K/Akt/mTORC1 and
ERK1/2 pathways by EGF is PTX insensitive [20,21]. In
this study, we also found that PTX did not block the acti-
vation of ERK1/2 by EGF (Additional file 1: Figure S1F).
We demonstrate a possible third avenue in which Giα
proteins differentially regulate RTK-mediated activation
of the PI3K/Akt/mTORC1 and ERK1/2 signaling path-
ways. We previously showed that Giα proteins acted
downstream of EGFR, but upstream of Gab1, leading to
Gab1 phosphorylation and its subsequent interaction
with PI3Kp85 in PI3K/Akt/mTORC1 signaling [20]. In
this study, we show that Giα proteins are also importantfor ERK1/2 activation by EGF. Giα proteins formed a
complex with the EGFR, its adaptor Gab1 and phosphat-
ase Shp2 in response to EGF, and loss of Giα proteins
impaired EGF-induced interaction of Gab1 with Shp2,
which is crucial for the activation of ERK1/2 by EGF
[30]. As a consequence, loss of Giα proteins led to a de-
fect in the activation of Akt and ERK1/2 by EGF and
HB-EGF. However, the relationship between Giα pro-
teins and EGFR is currently unclear. A recent study sug-
gested that EGF induced the formation of a Giα-GIV/
Girdin-EGFR complex activating the PI3K-Akt pathway,
and the interaction of Gi3α with EGFR was dependent
on the guanine exchange factor (GEF) motif in GIV [31].
GIV catalyzed the conversion of GDP-Gi3α to GTP-Gi3α,
and its GEF motif was important for autophosphoryl-
ation of EGFR and its localization and degradation in
AB
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Figure 5 Giα proteins are required for phosphorylation of Shp2
but not FAK1 in response to EGF, bFGF and IGF-1. WT and Gi1/3
DKO MEFs were treated with (A) EGF (100 ng/ml), (B) bFGF
(25 ng/ml), or (C) IGF-1 (20 ng/ml) for 0, 2, 5 or 15 min. p-FAK(Y397),
p-Gab1(Y627), p-Shp2(Y508) and β-actin were detected by IB via
anti-p-FAK(Y397), anti-p-Gab1(Y627), anti-p-Shp2(Y508) and anti-β-
actin antibodies, respectively. Gab1 and Shp2 were also detected
by IB (Additional file 5: Figure S5). Experiments were repeated two
times and similar results were obtained.
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the conversion of GDP-Gi3α to GTP-Gi3α by GIV regu-
lates its downstream Gβγ subunits in EGF signaling.
Unlike EGFRs, insulin receptor (IR), IGF-1 receptor
(IGF-1R) and FGF receptors (FGFRs) have their own
adaptor proteins: FRS2 and IRSs, respectively. FRS2 is cru-
cial for intracellular signaling in response to FGF [18,32]
and its interaction with Grb2 is critical for ERK1/2 activa-
tion by bFGF [33]. We found that this association was in-
tact in Giα deficient cells. This explains why ERK1/2
activation by aFGF and bFGF was observed in Giα defi-
cient cells. Further, FRS2 interacts with Gab1 and is re-
quired for Gab1’s associations with Grb2 and PI3Kp85 as
well as PI3K activation [27,34]. We identified that FRS2’sinteraction with Gab1 or the interaction of Gab1 with
Grb2 was impaired in Giα deficient cells. As a result, the
activation of Akt and mTORC1 by aFGF and bFGF was
diminished in Giα deficient cells revealing a new Giα/
FRS2/Grb2/Gab1-PI3K cascade in FGF signaling.
IR and IGFR bind IRSs, which directly interact with
PI3Kp85 leading to the activation of PI3K, Akt and
mTORC1 [35]. Therefore, the activation of Akt and
mTORC1 by IGF-1 and insulin was not largely reduced
in Giα-deficient MEFs or was even enhanced in Gab1-
deficient liver in response to insulin [36]. Conversely,
the activation of ERK1/2 was not altered in IRS-1-
deficient cells in response to IGF-1 [19], indicating that
other proteins are required for ERK1/2 activation by
IGF-1. Indeed, our data showed that loss of Giα proteins
severely impaired ERK1/2 activation by IGF-1 and insu-
lin. Intriguingly, although loss of Giα proteins exhibited
a minor defect in Akt activation, the S6 phosphorylation
was clearly impaired in Gi1/3-deficient MEFs (Figures 1E
and 1F). The possible interpretation is that S6 can also
be phosphorylated by other protein kinases such as
p90RSK, which is a substrate of ERK1/2 and is able to
phosphorylate S6 when mTORC1 activity is inhibited
[37]. In addition, our data showed that PTX was able to
reduce insulin-induced ERK1/2 activation (Additional 1:
Figure S1F). This result suggests that GiαPCRs may be
involved in the activation of ERK1/2 by insulin.Giα proteins in breast cancer
Giα proteins are highly expressed in some breast cancer
cells, especially in metastatic breast cancer cells [38].
Giα proteins have been implicated in breast cancer inva-
sion in response to SDF1, which is the only ligand for
GiαPCR CXCR4. Upregulation of CXCR4 is vital for
Her2-mediated metastasis of breast cancer [39,40]. Inter-
estingly, the association of Giα proteins with Gβγ is con-
sidered a prerequisite for functional CXCR4 [38]. In the
present study, we found that Giα proteins not only regu-
lated SDF1-mediated invasion of breast cancer (data not
shown), but also controlled EGF-, bFGF-, IGF-1- and
serum-induced MB231 invasion. Additionally, Giα pro-
teins regulated breast cancer growth.
Overexpression of RTKs such as EGFR family mem-
bers and FGFRs is a hallmark of breast cancer. This
phenotypic overexpression promotes activity of RTKs
leading to overactivation of their downstream events and
cascades, including Gabs [41,42], Shp2 [43] and the
PI3K/Akt/mTORC1 and Ras/ERK1/2 signaling pathways
leading to progression, invasion and metastasis of breast
cancer [44,45]. We showed that Giα proteins associated
with active EGFR and FGFR, as well as their down-
stream adaptor proteins and Shp2 in response to re-
spective agonists. Further, Giα proteins can differentially
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Figure 6 Giα proteins associate with RTKs and their adaptor proteins in breast cancer cells, and are important for interactions of Gab1
with Shp2 or Grb2 in MEFs in response to EGF or bFGF. (A) MB231 cells were treated with bFGF (25 ng/ml) for 0, 2 or 5 min. Whole cell
lysates were prepared. The associations of Gi3α with p-FGFR, Gab1 and FRS2 were determined by IB using anti-p-FGFR(Y766), anti-Gab1, anti-FRS2
and anti-Gi3α antibodies, respectively. (B-D) MB231 cells were treated with EGF (100 ng/ml) for 0, 2, 5, 10 or 20 min. The associations of Gi3α with
p-EGFR, EGFR (B), Gab1 and Shp2 (C & D) were determined by IB using anti-p-EGFR (Y1173), anti-EGFR, anti-Gab1, anti-Shp2 and anti-Gi3α
antibodies, respectively. (E & F) WT and Gi1/3 DKO MEFs were treated with EGF or bFGF for 0, 2 or 5 min. The association of Shp2 with Gab1
in response to EGF (E), and the associations of Grb2 with Gab1 and FRS2 in response to bFGF (F) were determined by IB. Experiments were
repeated two to four times. Similar results were obtained.
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EGF, bFGF and IGF-1 in breast cancer cells.
In summary, our results demonstrate that Giα proteins
are important regulators of RTK signaling in normal cells
and in breast cancer cells. Giα proteins differentially regu-
late the activation of Akt, mTORC1 and ERK1/2 by differ-
ent growth factors. Given the fact that growth factors and
their RTKs are critical for breast cancer progression, inva-
sion and metastasis, pharmacological interference of Giα
protein function may provide an alternative therapeutic
strategy for breast cancer treatment.
Materials and method
Antibodies
Antibodies raised against EGFR (sc-03), Gi1α (sc-391),
Gi2α (sc-7276), Gi3α (sc-262), AKT1/2 (sc-8312), ERK1/2
(sc-94), FRS2 (sc-8318) and SH-PTP2 (Shp2, sc-280)
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-β-actin antibody was purchased from
Sigma-Aldrich (St. Louis, Mo). Anti-EGFR, anti-FGFR,
anti-Gab1, anti-IGF-1R, and other anti-phospho anti-
bodies were purchased from Cell Signaling Technology
(Danvers, MA).Cell line and culture
WT and Gi1/3 DKO MEFs were characterized and
cultured as previous described [20]. MDA-MB-231-
D3H2-LN (MB231) cells were purchased from Caliper
Life Science (Hopkinton, MA). Cells were cultured in
DMEM high-glucose medium supplemented with 10%
FBS in a CO2 incubator at 37°C.Immunoblotting analysis
WT, DKO, transfected or siRNA knockdown cells were
starved overnight (o/n), and then treated with bFGF, EGF,
HB-EGF (Invitrogen), aFGF (Cell Signaling), IGF-1 (Invi-
trogen and R & D Systems), or insulin (BD Pharmingen)
for the indicated time points. Cells were washed twice with
cold 1× phosphate buffered saline (PBS) and lysed with a
lysis buffer [1% Triton ×-100, 150 mM NaCl, 50 mM Tris-
Cl, pH 7.4, 0.5 mM EDTA, 1 mM sodium orthovanadate,
5 mM beta glycerol phosphate, 1× protease inhibitor
cocktail (Roche, Indianapolis, IN)] [46]. Total of 30–
60 μg protein lysates were boiled in the sample buffer,
separated on 10% SDS-PAGE and transferred onto
PVDF membranes (Millipore, Billerica, MA) followed
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(Pierce, Rockford, IL).
Immunoprecipitation
Cells were cultured to 70% confluence and then starved
o/n. Cells were treated with EGF, or bFGF for different
time points and then lysed with the lysis buffer. For each
sample, 600–800 μg of proteins were pre-cleared by in-
cubation with 40 μl of protein A/G Sepharose (beads)
(Amersham, IL) for 30 minutes at 4°C. After an over-
night incubation at 4°C with specific antibodies (2–4 μg/
mg protein), 40 μl of protein A/G bead suspensions were
added to the complexes and incubated for another
2 hours. Then the beads were washed three times with
washing buffer (lysis buffer containing 1 mM PMSF) and
once with 1× PBS. The boiled proteins were separated
on 10% SDS-PAGE gels and transferred onto PVDF
membranes followed by incubation with different anti-
bodies and detection with ECL.
Plasmid transfection
Lipofectamine 2000 (Invitrogen) was used as the trans-
fection reagent. 3.5×105 Gi1/3 DKO cells were seeded in
6-well plates and cultured in DMEM supplemented with
10% FBS without antibiotics. Five μg Gi1α or Gi3α plas-
mids in 250 μl of serum free medium (SFM) and 10 μl
Lipofectamine 2000 in 250 μl of SFM were gently mixed
and incubated for 30 min. The plasmid-Lipofectamine
complexes were then added to each well. After 5 hours
the medium was replaced with complete medium. Cells
were cultured for additional 14 hours, starved o/n and
then treated with growth factors as described above.
siRNA transfaction
Human and mouse Gi1α, Gi2α, and Gi3α siRNA duplexes
were purchased from Santa Cruz Biotechnology. Cells
were cultured in 10% FBS DMEM in the absence of anti-
biotics to 70% confluence at the time of transfection.
Lipofectimine RNAiMAX Reagent (7.5 μl, Invitrogen) in
250 μl SFM, and 3.5 μl of Gi1α, Gi2α or Gi3α siRNA du-
plexes in another 250 μl SFM were gently combined,
mixed, and incubated for 25 min at room temperature.
The siRNA duplexes-RNAiMAX complexes were added
to culture with a final RNA concentration of 10 nM in a
total volume of 3 ml. After 16 hours, the medium was
replaced by complete medium. Cells were cultured for
another 24 hours and then starved o/n followed by treat-
ment for immunoblotting analysis or in vitro invasion
assay.
Breast cancer cell in vitro invasion assay
Cell invasion assay was performed using Costar Trans-
well permeable support (8.0-μm pore size, Corning, NY)
in 24-well plates. The starved mock, Gi1/3, Gi1/2/3siRNA knockdown MB231 cells were harvested with
trypsin, resuspended at 5×104 cells/ml in SFM contain-
ing 0.1% BSA, and 200 μl of each type of cells were
added to the upper chambers coated with Matrigel
(1 mg/ml, BD Pharmingen). The lower chambers were
filled with 600 μl SFM or SFM containing EGF, IGF-1,
bFGF or 10%FBS. After 36 hours culture, cells were
stained with HEME 3 Solution (Fisher Diagnostics,
Middletown, VA), and non-invaded cells on the top of
the transwell were removed with cotton swabs. Invaded
cells were counted under an Olympus CKX41 micros-
copy (Olympus, Japan) and recorded by an Infinity 2
camera (Electron Microscopy Sciences, Hatfield, PA).
Breast cancer cell growth assay
siRNA knockdown MB231 cells (scrambled siRNA du-
plexes (mock) or Gi1/2/3 siRNA duplexes) (1×104 cells/
well) were seeded in 6-well plates in DMEM medium
containing 5% or 10% FBS. From day 1, at least three
fields in each well were randomly selected for recording
images and counting cells under an Olympus CKX41
microscopy with an Infinity 2 camera. Experiments were
repeated twice.
Statistical analysis
Statistical difference between two groups was evaluated
using Student’s t test. P values less than 0.05 were con-
sidered significant. Data were presented as mean ± SD.
Additional files
Additional file 1: Figure S1. (A) Left panel: Expression of Gi1α (Gi1),
Gi2α (Gi2) and Gi3α (Gi3) in WT and Gi1/3 DKO MEFs. WT and Gi1/3DKO
MEFs were lysed and the expression levels of Giα proteins were
determined by IB using anti-Gi1α, anti-Gi2α and anti-Gi3α antibodies,
respectively. Right panel: Expression of Gi1 and Gi2 in mouse brain
tissues. Whole cell lysates of WT, Gi2αF/F/Mx1Cre (Gi2F/F/Mx1CRE) (without
induction) and Gi2αF/F/Gi1/3DKO (Gi2F/F/Gi1/3DKO) mouse brain tissues
were used to determine the expression levels of Gi1 and Gi2. (B-D) The
expression levels of Akt, ERK1/2, Gab1, EGFR, FGFR, IGF-1R and β-actin in
WT and Gi1/3 DKO MEFs were determined by IB. (E) Loss of Gi2α (Gi2) did
not decrease ERK1/2 activation by EGF. (F) PTX did not block ERK
activation by EGF, but reduced ERK1/2 activation by insulin.
Additional file 2: Figure S2. Knockdown of Gi2α reduced Akt(S473)
phosphorylation, but not did inhibit ERK1/2 and S6 phosphorylation in
response to EGF. MB231 cells were transfected with scrambled (mock) or
Gi2αsiRNA (Gi2siRNA) duplexes. Cells were treated with EGF for the
indicated time points. p-Akt(S473S), p-ERK1/2(T202/Y204), p-S6(S235/236),
Gi2α (Gi2) and β-actin were detected by IB.
Additional file 3: Figure S3. Knockdown of Gi1α, Gi2α and Gi3α in
breast cancer cells impairs their growth ability. MB231 cells were
transfected with scrambled or siRNA duplexes [combination of Gi1α, Gi2α
and Gi3α (Gi1/2/3)]. After 24 hours, cells were trypsinized, seeded in
6-well plates and cultured in DMEM containing 5% or 10% FBS for up to
6 days. Cells were observed under an Olympus CKX41 microscope and
recorded by an Infinity 2 camera.
Additional file 4: Figure S4. Knockdown of Gi2α in breast cancer cells
did not impair their invasion ability in response to EGF, bFGF and IGF-1.
MB231 cells were transfected with scrambled or Gi2αsiRNA (Gi2siRNA)
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were re-trypsinized, seeded into 8 μm transwells pre-coated with matrigel
and exposed to EGF (100 ng/ml), bFGF (25 ng/ml), IGF-1 (20 ng/ml), or
left untreated (with serum free medium) for 36 hours. Penetrated cells
were stained and recorded.
Additional file 5: Figure S5. Loss of Gi1α and Gi3α impairs Akt(S473)
and ERK1/2(T202/Y204) phosphorylation in response to EGF, and S6(S235/
236) phosphorylation in response to IGF-1.
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